Theravance Biopharma stock initiated with Buy rating at B.Riley on respiratory therapy growth

B.Riley initiated coverage on Theravance Biopharma (TBPH) with a Buy rating and a $28.00 price target, citing the company's strong financial position following a $275 million non-core asset monetization and its undervalued core growth drivers. The firm highlighted Yupelri, generating $270 million in annualized revenue with patent protection extending over a decade, and ampreloxetine, a Phase 3 asset with a 'highly de-risked' upcoming readout and significant peak sales potential, which B.Riley believes is significantly undervalued by the current enterprise value. This positive outlook is further supported by TBPH's strong Q2 2025 results, which surpassed analyst expectations, and recent positive commentary from other firms like BTIG and Leerink Partners.

Analysis

B.Riley's initiation of coverage on Theravance Biopharma (TBPH) with a 'Buy' rating and a $28 price target highlights a significant undervaluation thesis. The firm's analysis points to a post-restructuring enterprise value of approximately $400 million, which it argues does not adequately reflect the company's two core assets. The first is the Viatris-partnered Yupelri, a commercial drug for COPD generating around $270 million in annualized revenue with a growth rate of approximately 20% year-over-year. Crucially, recent patent litigation settlements have secured its cash flows by delaying generic competition for over a decade. The second key asset is the late-stage drug candidate ampreloxetine, whose upcoming Phase 3 trial readout is described as 'highly de-risked' and which holds a peak risk-adjusted sales potential of about $550 million. This bullish outlook is substantiated by the company's robust financial health, evidenced by a $275 million cash injection from monetizing its Trelegy royalty and a strong Q2 2025 earnings report, where EPS of $1.08 and revenue of $26.2 million significantly surpassed analyst estimates of $0.67 and $15.92 million, respectively. The positive sentiment is further corroborated by supportive actions from other firms, including a reiterated 'Buy' from BTIG and a raised price target from Leerink Partners.

Key Decisions for Investors

• Investors should consider the compelling valuation argument that TBPH's current enterprise value of ~$400M may not fully price in the durable, growing cash flows from Yupelri and the significant peak sales potential of ampreloxetine.
• The primary forward-looking catalyst is the Phase 3 CYPRESS trial data for ampreloxetine, expected in Q1 2026; a positive readout is positioned as a major de-risking event that could drive substantial share price appreciation.
• Monitor the execution on Yupelri's commercial performance, as its ~20% YoY growth provides a fundamental support to the valuation while the company's strengthened balance sheet mitigates financing risk ahead of the pivotal trial data.